Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1949 1
1950 2
1951 1
1953 1
1954 2
1955 2
1956 1
1957 1
1958 1
1962 1
1964 1
1965 1
1966 4
1967 1
1968 3
1969 6
1970 6
1971 2
1972 6
1973 7
1974 11
1975 7
1976 11
1977 6
1978 4
1979 4
1980 5
1981 4
1982 6
1983 7
1984 11
1985 5
1986 3
1987 6
1988 4
1989 8
1990 3
1991 6
1992 8
1993 6
1994 8
1995 6
1996 11
1997 8
1998 6
1999 5
2000 4
2001 6
2002 6
2003 9
2004 5
2005 9
2006 6
2007 5
2008 8
2009 2
2010 4
2011 4
2012 3
2013 3
2014 4
2015 3
2016 8
2017 5
2018 2
2019 3
2020 4
2021 4
2022 3
2023 3
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

326 results

Results by year

Filters applied: . Clear all
Page 1
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, Labriola D, Moussa SE, Neff GW, Rinella ME, Anstee QM, Abdelmalek MF, Younossi Z, Baum SJ, Francque S, Charlton MR, Newsome PN, Lanthier N, Schiefke I, Mangia A, Pericàs JM, Patil R, Sanyal AJ, Noureddin M, Bansal MB, Alkhouri N, Castera L, Rudraraju M, Ratziu V; MAESTRO-NASH Investigators. Harrison SA, et al. Among authors: taub r. N Engl J Med. 2024 Feb 8;390(6):497-509. doi: 10.1056/NEJMoa2309000. N Engl J Med. 2024. PMID: 38324483 Clinical Trial.
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Harrison SA, Bashir MR, Guy CD, Zhou R, Moylan CA, Frias JP, Alkhouri N, Bansal MB, Baum S, Neuschwander-Tetri BA, Taub R, Moussa SE. Harrison SA, et al. Among authors: taub r. Lancet. 2019 Nov 30;394(10213):2012-2024. doi: 10.1016/S0140-6736(19)32517-6. Epub 2019 Nov 11. Lancet. 2019. PMID: 31727409 Clinical Trial.
Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β agonist in clinical trials for the treatment of dyslipidemia.
Kelly MJ, Pietranico-Cole S, Larigan JD, Haynes NE, Reynolds CH, Scott N, Vermeulen J, Dvorozniak M, Conde-Knape K, Huang KS, So SS, Thakkar K, Qian Y, Banner B, Mennona F, Danzi S, Klein I, Taub R, Tilley J. Kelly MJ, et al. Among authors: taub r. J Med Chem. 2014 May 22;57(10):3912-23. doi: 10.1021/jm4019299. Epub 2014 Apr 8. J Med Chem. 2014. PMID: 24712661
Peritoneal mesothelioma.
Hesdorffer ME, Chabot J, DeRosa C, Taub R. Hesdorffer ME, et al. Among authors: taub r. Curr Treat Options Oncol. 2008 Jun;9(2-3):180-90. doi: 10.1007/s11864-008-0072-2. Epub 2008 Oct 8. Curr Treat Options Oncol. 2008. PMID: 18841478 Review.
Peritoneal mesothelioma.
Taub RN, Keohan ML, Chabot JC, Fountain KS, Plitsas M. Taub RN, et al. Curr Treat Options Oncol. 2000 Oct;1(4):303-12. doi: 10.1007/s11864-000-0046-5. Curr Treat Options Oncol. 2000. PMID: 12057156 Review.
326 results